Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. decreased its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 30.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 93,807 shares of the medical device company's stock after selling 40,640 shares during the quarter. Alliancebernstein L.P. owned 0.14% of Tandem Diabetes Care worth $3,379,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares in the last quarter. State Street Corp grew its position in Tandem Diabetes Care by 3.2% in the third quarter. State Street Corp now owns 2,655,736 shares of the medical device company's stock worth $112,630,000 after acquiring an additional 83,172 shares during the period. GW&K Investment Management LLC raised its position in Tandem Diabetes Care by 18.0% in the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after purchasing an additional 323,674 shares during the period. Stephens Investment Management Group LLC lifted its stake in shares of Tandem Diabetes Care by 22.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock valued at $56,040,000 after purchasing an additional 281,327 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Tandem Diabetes Care by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,525,816 shares of the medical device company's stock worth $64,722,000 after purchasing an additional 18,187 shares during the period.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM traded down $0.40 during trading hours on Friday, hitting $16.86. The company had a trading volume of 1,132,393 shares, compared to its average volume of 1,505,814. The business has a 50 day moving average of $21.77 and a 200-day moving average of $30.04. The company has a market cap of $1.12 billion, a PE ratio of -8.74 and a beta of 1.52. Tandem Diabetes Care, Inc. has a 1-year low of $15.75 and a 1-year high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.

Insider Buying and Selling

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TNDM shares. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Mizuho initiated coverage on shares of Tandem Diabetes Care in a report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 target price for the company. Canaccord Genuity Group restated a "buy" rating and set a $63.00 price target on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Barclays cut their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, The Goldman Sachs Group dropped their target price on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.88.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.